A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
Trial details
- Registry ID
- NCT07298330
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as BJT-778; BTG
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)NCT07298330 | MIRM | Phase 3 | Active not recruiting | 2026-08Estimated |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionNCT06907290 | MIRM | Phase 2, Phase 3 | Active not recruiting | 2029-05Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |